普立维托治疗的关键挑战:尿失禁和抗凝患者。

IF 1 Q4 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Journal of nuclear medicine technology Pub Date : 2023-12-05 DOI:10.2967/jnmt.123.266482

James R Crowley

{"title":"普立维托治疗的关键挑战:尿失禁和抗凝患者。","authors":"James R Crowley","doi":"10.2967/jnmt.123.266482","DOIUrl":null,"url":null,"abstract":"As molecular therapy continues to grow, unanticipated challenges may arise, requiring the institution's therapeutic team to reevaluate its therapeutic protocol to identify and address potential situations and challenges that may occur. This practical pointer will focus on the novel prostate cancer therapy Pluvicto (177Lu-vipivotide tetraxetan) and 2 unique situations and challenges of treating patients at the Theranostic Center at Carilion Clinic, an outpatient facility dedicated to targeted molecular therapy.","PeriodicalId":16548,"journal":{"name":"Journal of nuclear medicine technology","volume":" ","pages":"279-281"},"PeriodicalIF":1.0000,"publicationDate":"2023-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Critical Challenges in Pluvicto Therapy: Incontinent and Anticoagulated Patients.\",\"authors\":\"James R Crowley\",\"doi\":\"10.2967/jnmt.123.266482\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"As molecular therapy continues to grow, unanticipated challenges may arise, requiring the institution's therapeutic team to reevaluate its therapeutic protocol to identify and address potential situations and challenges that may occur. This practical pointer will focus on the novel prostate cancer therapy Pluvicto (177Lu-vipivotide tetraxetan) and 2 unique situations and challenges of treating patients at the Theranostic Center at Carilion Clinic, an outpatient facility dedicated to targeted molecular therapy.\",\"PeriodicalId\":16548,\"journal\":{\"name\":\"Journal of nuclear medicine technology\",\"volume\":\" \",\"pages\":\"279-281\"},\"PeriodicalIF\":1.0000,\"publicationDate\":\"2023-12-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of nuclear medicine technology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2967/jnmt.123.266482\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of nuclear medicine technology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2967/jnmt.123.266482","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

摘要

随着分子疗法的不断发展，可能会出现意想不到的挑战，要求机构的治疗团队重新评估其治疗方案，以识别和应对可能发生的潜在情况和挑战。本实用指南将重点介绍新型前列腺癌治疗药物Pluvicto (177Lu-vipivotide tetraxetan)，以及Carilion诊所治疗中心治疗患者的2种独特情况和挑战。Carilion诊所是一家致力于靶向分子治疗的门诊机构。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Critical Challenges in Pluvicto Therapy: Incontinent and Anticoagulated Patients.

As molecular therapy continues to grow, unanticipated challenges may arise, requiring the institution's therapeutic team to reevaluate its therapeutic protocol to identify and address potential situations and challenges that may occur. This practical pointer will focus on the novel prostate cancer therapy Pluvicto (¹⁷⁷Lu-vipivotide tetraxetan) and 2 unique situations and challenges of treating patients at the Theranostic Center at Carilion Clinic, an outpatient facility dedicated to targeted molecular therapy.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of nuclear medicine technology RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING-

CiteScore

1.90

自引率

15.40%

发文量